Abstract: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.
Inventors:
Alberto Cerri, Giorgio Fedrizzi, Alessandra Benicchio, Giuseppe Bianchi, Patrizia Ferrari, Mauro Gobbini, Rosamaria Micheletti, Marco Pozzi, Piero Enrico Scotti
Abstract: The present invention relates to new retinoid derivatives of formula I and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumors, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.
Abstract: The present invention relates to novel pharmaceutical compositions in which the active agent is a topoisomerase I inhibitor, in particular a camptothecin derivative, that is useful for the treatment and prevention of proliferative diseases including cancer.
Abstract: A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof.
Abstract: The invention, described herein, is directed to the use of acetyl. L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in winch said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.
Abstract: The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable.
Abstract: The use of resveratrol is described fir the preparation of a medicament for the treatment of influenza. Said medicament exerts itself in therapeutic activity through inhibition of viral replication.
Abstract: L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or their pharmaceutically acceptable salts, are used in combination to treat oligoasthenoteratosperia including oligospermia, asthenospermia, and teratospermia.
Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.
Abstract: The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance.
Abstract: The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable.
Abstract: The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds.
Inventors:
Giuseppe Giannini, Walter Cabri, Daniele Simoni, Riccardo Baruchello, Claudio Pisano, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati
Abstract: It is described a composition in the form of eye drops or ointment, comprising as active ingredients L-carnitine or a physiologically acceptable salt thereof; and 3-Hydroxykynurenine O-?-DL-glucoside, useful for preventing or treating pathologies of the eyes due to ultraviolet radiation.
Abstract: Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.
Abstract: Use of L-carnitine and/or one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of a dietary supplement or medicament for the treatment of corneal diseases is disclosed.
Abstract: It is described a combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.
Abstract: Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin El, pentolamine and papaverine.
Abstract: It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.
Abstract: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumor selectivity.
Abstract: A container for a vial of radiopharmaceutical, made of polymethyl methacrylate consists of a receptacle, with a cavity capable of containing the vial of radiopharmaceutical, and of a lid screwed onto the receptacle for closing the container, said lid presenting a central through-hole. A set, in combination with this container with the vial of radiopharmaceutical, consisting of a bottle of saline solution and two infusion catheters, enhances the radioprotection during the infusion of a radiopharmaceutical in an infusion operation.